| Autor: |
Rikhi N; Longhorn Vaccines and Diagnostics, Gaithersburg, MD 20878, USA., Sei CJ; Longhorn Vaccines and Diagnostics, Gaithersburg, MD 20878, USA., Rao M; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA., Schuman RF; Antibody and Immunoassay Consultants, Rockville, MD 20850, USA., Kroscher KA; Longhorn Vaccines and Diagnostics, Gaithersburg, MD 20878, USA., Matyas GR; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA., Muema K; Longhorn Vaccines and Diagnostics, Gaithersburg, MD 20878, USA., Lange C; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA., Assiaw-Dufu A; Longhorn Vaccines and Diagnostics, Gaithersburg, MD 20878, USA., Hussin E; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA., Jobe O; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA., Alving CR; U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA., Fischer GW; Longhorn Vaccines and Diagnostics, Gaithersburg, MD 20878, USA. |
| Abstrakt: |
An unconjugated composite peptide vaccine targeting multiple conserved influenza epitopes from hemagglutinin, neuraminidase, and matrix protein and formulated with a safe and highly potent adjuvant, Army Liposome formulation (ALFQ), generated broad and durable immune responses in outbred mice. The antibodies recognized specific epitopes in influenza peptides and several human, avian, and swine influenza viruses. Comparable antibody responses to influenza viruses were observed with intramuscular and intradermal routes of vaccine administration. The peptide vaccine induced cross-reactive antibodies that recognized influenza virus subtypes A/H1N1, A/H3N2, A/H5N1, B/Victoria, and B/Yamagata. In addition, immune sera neutralized seasonal and pandemic influenza strains (Group 1 and Group 2). This composite multi-epitope peptide vaccine, formulated with ALFQ and administered via intramuscular and intradermal routes, provides a high-performance supra-seasonal vaccine that would be cost-effective and easily scalable, thus moving us closer to a viable strategy for a universal influenza vaccine and pandemic preparedness. |
